| Literature DB >> 22389844 |
Abstract
A series of quinoline-based agents with CNS activity have been analyzed for their three-dimensional similarity with respect to a set of standard atypical antipsychotics. The method aligns the molecules based on their molecular fields represented as local extrema of electrostatic, van der Waals, and hydrophobic potentials of the molecule termed "field points." The compounds in the series were found to demonstrate relatively lesser 3D similarity to the dibenzodiazepine derivative clozapine. Similarity values were higher with respect to extended chain compounds ketanserin, ziprasidone, and risperidone. The results obtained were found to agree with the physicochemical similarity of the compounds reported earlier.Entities:
Year: 2011 PMID: 22389844 PMCID: PMC3263725 DOI: 10.5402/2011/186943
Source DB: PubMed Journal: ISRN Pharm ISSN: 2090-6145
Chemical structures and results in pharmacological testing [16].
|
|
*Show blockade only in apomorphine-induced stereotypy assay indicative of potential to cause extrapyramidal symptoms.
Similarity of test compounds with respect to risperidone and ketanserin.
| Compd. no. | Similarity | Field similarity | Field score | Vol. Similarity | Volume score | Shape similarity | Shape score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ris. | Ket. | Ris. | Ket. | Ris. | Ket. | Ris. | Ket. | Ris. | Ket. | Ris. | Ket. | Ris. | Ket. | |
|
| 0.620 | 0.672 | 0.483 | 0.539 | −48.519 | −52.436 | 0.806 | 0.787 | 204.854 | 193.544 | 0.756 | 0.804 | 192.146 | 197.828 |
|
| 0.619 | 0.648 | 0.541 | 0.480 | −50.853 | −46.808 | 0.709 | 0.784 | 201.876 | 191.679 | 0.697 | 0.815 | 175.958 | 199.110 |
|
| 0.659 | 0.686 | 0.552 | 0.576 | −55.523 | −57.483 | 0.783 | 0.802 | 198.906 | 197.155 | 0.766 | 0.795 | 193.085 | 193.834 |
|
| 0.610 | 0.683 | 0.525 | 0.565 | −49.877 | −55.710 | 0.748 | 0.772 | 189.082 | 188.609 | 0.696 | 0.801 | 175.690 | 195.756 |
|
| 0.661 | 0.689 | 0.542 | 0.594 | −53.226 | −59.520 | 0.740 | 0.799 | 194.220 | 203.325 | 0.781 | 0.783 | 205.048 | 199.232 |
|
| 0.626 | 0.659 | 0.512 | 0.501 | −48.374 | −49.907 | 0.770 | 0.803 | 200.828 | 202.951 | 0.740 | 0.818 | 193.227 | 206.720 |
|
| 0.676 | 0.721 | 0.581 | 0.635 | −56.250 | −64.061 | 0.824 | 0.820 | 216.246 | 208.667 | 0.772 | 0.808 | 202.659 | 205.442 |
|
| 0.658 | 0.716 | 0.549 | 0.610 | −53.264 | −58.534 | 0.745 | 0.802 | 194.555 | 202.734 | 0.768 | 0.823 | 200.627 | 208.108 |
|
|
|
|
|
| − | − |
|
|
|
|
|
|
|
|
Similarity of test compounds with respect to ziprasidone and clozapine.
| Compd. no. | Similarity | Field similarity | Field score | Vol. similarity | Volume score | Shape similarity | Shape score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zip. | Clz. | Zip. | Clz. | Zip. | Clz. | Zip. | Clz. | Zip. | Clz. | Zip. | Clz. | Zip. | Clz. | |
|
| 0.696 | 0.566 | 0.639 | 0.540 | −66.121 | −50.871 | 0.798 | 0.620 | 201.876 | 141.337 | 0.752 | 0.592 | 190.325 | 134.964 |
|
| 0.651 | 0.567 | 0.564 | 0.482 | −58.038 | −41.151 | 0.741 | 0.649 | 186.210 | 147.078 | 0.738 | 0.652 | 185.787 | 147.697 |
|
| 0.652 | 0.558 | 0.557 | 0.521 | −58.139 | −47.685 | 0.772 | 0.589 | 195.325 | 134.285 | 0.747 | 0.595 | 187.604 | 134.470 |
|
| 0.632 | 0.579 | 0.575 | 0.484 | −59.279 | −43.358 | 0.708 | 0.586 | 178.021 | 132.880 | 0.689 | 0.674 | 173.209 | 152.661 |
|
| 0.703 | 0.583 | 0.603 | 0.553 | −59.824 | −49.015 | 0.730 | 0.624 | 190.885 | 147.619 | 0.802 | 0.622 | 209.751 | 147.293 |
|
| 0.603 | 0.590 | 0.457 | 0.556 | −45.789 | −48.918 | 0.778 | 0.569 | 202.276 | 133.575 | 0.749 | 0.625 | 194.708 | 146.938 |
|
| 0.675 | 0.571 | 0.599 | 0.556 | −62.140 | −52.714 | 0.786 | 0.615 | 205.549 | 145.517 | 0.711 | 0.585 | 185.959 | 138.252 |
|
| 0.675 | 0.573 | 0.606 | 0.539 | −63.004 | −49.314 | 0.730 | 0.654 | 189.892 | 153.728 | 0.744 | 0.606 | 193.411 | 142.511 |
|
|
|
|
|
| − | − |
|
|
|
|
|
|
|
|
Similarity of test compounds with respect to chlorpromazine and template.
| Compd. no. | Similarity | Field similarity | Field score | Vol. similarity | Volume score | Shape similarity | Shape score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CPZ | Temp | CPZ | Temp | CPZ | Temp | CPZ | Temp | CPZ | Temp | CPZ | Temp | CPZ | Temp | |
|
| 0.613 | 0.603 | 0.535 | 0.466 | −48.258 | −47.987 | 0.628 | 0.620 | 141.826 | 141.337 | 0.690 | 0.740 | 164.092 | 185.972 |
|
| 0.565 | 0.579 | 0.487 | 0.469 | −41.443 | −46.261 | 0.641 | 0.649 | 147.210 | 147.078 | 0.643 | 0.689 | 151.980 | 172.277 |
|
| 0.557 | 0.575 | 0.532 | 0.451 | −49.327 | −45.631 | 0.572 | 0.589 | 135.325 | 134.285 | 0.583 | 0.699 | 137.385 | 174.194 |
|
| 0.561 | 0.576 | 0.517 | 0.425 | −46.640 | −41.811 | 0.588 | 0.586 | 138.021 | 132.880 | 0.606 | 0.728 | 143.205 | 181.874 |
|
| 0.543 | 0.596 | 0.493 | 0.456 | −46.066 | −44.811 | 0.630 | 0.624 | 141.855 | 147.619 | 0.592 | 0.736 | 145.862 | 191.305 |
|
| 0.581 | 0.582 | 0.500 | 0.436 | −43.990 | −44.166 | 0.578 | 0.569 | 136.276 | 133.575 | 0.662 | 0.728 | 162.107 | 188.021 |
|
| 0.599 | 0.635 | 0.520 | 0.543 | −48.090 | −54.255 | 0.616 | 0.615 | 145.549 | 145.517 | 0.679 | 0.726 | 167.193 | 188.809 |
|
| 0.591 | 0.618 | 0.538 | 0.489 | −51.045 | −49.919 | 0.630 | 0.654 | 142.092 | 153.728 | 0.644 | 0.748 | 157.594 | 193.364 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Figure 1Alignment of compound 14 (thin sticks) with risperidone (a) and ketanserin (b). Risperidone and ketanserin are shown as capped sticks (pink). Tetrahedra and dodecahedra depict field points for 14 and reference compounds, respectively. Blue, maroon, yellow, and brown colors depict negative field, positive field, surface field, and hydrophobic field points.
Figure 3Alignment of compound 14 (thin sticks) with three compound templates generated from risperidone, ketanserin, and ziprasidone shown as capped sticks (pink). Field point depiction is the same as in Figure 1.